(1) AstraZeneca $AZN and collab partner Merck $MRK announce the FDA nod for the use of Lynparza (olaparib), combined with bevacizumab (Roche's Avastin), as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary...